Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0
|
作者：
Samuel Murray
Vasilios Karavasilis
Mattheos Bobos
Evangelia Razis
Savvas Papadopoulos
Christos Christodoulou
Paris Kosmidis
George Fountzilas
机构：
[1] BioMarker Solutions Ltd,Department of Molecular Oncology
[2] GeneKOR,Department of Medical Oncology
[3] “Papageorgiou” Hospital,Department of Pathology
[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[6] “Hygeia” Hospital,Second Department of Medical Oncology
[7] “Hygeia” Hospital,Second Department of Medical Oncology
[8] “Metropolitan” Hospital,undefined
[9] “Hygeia” Hospital,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词：
Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
    Perol, M.
    Arpin, D.
    REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
  • [42] Non small cell lung cancer (NSCLC) xenografts as models for the prediction of response to tyrosine kinase inhibitors
    Fichtner, Iduna
    Rolff, Jana
    Soong, Richie
    Becker, Michael
    Lee, Sumarlin
    Sommer, Anette
    Merk, Johannes
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3528S - 3528S
  • [43] Heterogeneity of response to tyrosine kinase inhibitors between primary tumors and matched metastases in Non-Small-Cell Lung Cancers
    Cortot, Alexis B.
    Duruisseaux, Michael
    Arpin, Dominique
    Perrot, Emilie
    Geriniere, Laurence
    Perol, Maurice
    Souquet, Pierre-Jean
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S675 - S675
  • [44] Inhibitors of the epidermal growth factor receptor tyrosine kinase: targeted therapy hits the Bullseye in patients with non-small-cell lung cancer
    Kris, MG
    LUNG CANCER, 2004, 45 : S6 - S6
  • [45] Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: a case series and review of the literature
    Akinori Sasaki
    Yutaro Fujimoto
    Takashi Inada
    Azusa Ishizuka
    Jun Ehara
    Shin Ogita
    Yasuhiro Norisue
    Journal of Medical Case Reports, 17
  • [46] Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: a case series and review of the literature
    Sasaki, Akinori
    Fujimoto, Yutaro
    Inada, Takashi
    Ishizuka, Azusa
    Ehara, Jun
    Ogita, Shin
    Norisue, Yasuhiro
    JOURNAL OF MEDICAL CASE REPORTS, 2023, 17 (01)
  • [47] EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer
    Kamel-Reid, S.
    Chong, G.
    Ionescu, D. N.
    Magliocco, A. M.
    Spatz, A.
    Tsao, M.
    Weng, X.
    Young, S.
    Zhang, T.
    Soulieres, D.
    CURRENT ONCOLOGY, 2012, 19 (02) : E67 - E74
  • [48] Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
    Vavala, Tiziana
    Mariniello, Annapaola
    Novello, Silvia
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S48 - S54
  • [49] Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer
    Rosell, R
    Ichinose, Y
    Taron, M
    Sarries, C
    Queralt, C
    Mendez, P
    Sanchez, JM
    Nishiyama, K
    Moran, T
    Cirauqui, B
    Mate, JL
    Besse, B
    Reguart, N
    Perez, M
    Sanchez, JJ
    LUNG CANCER, 2005, 50 (01) : 25 - 33
  • [50] Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors
    Zwitter, Matjaz
    Rossi, Antonio
    Di Maio, Massimo
    Perme, Maja Pohar
    Lopes, Gilberto
    RADIOLOGY AND ONCOLOGY, 2017, 51 (03) : 241 - 251
12345